Startups · AI

Senior Scientist, Lentiviral Vector Cell Line Development

Asimov · Boston, MA · On-site

← All jobs
About Asimov

End-to-end data and teleoperation services for embodied AI. From egocentric capture to remote operation. Backed by Y Combinator and a16z.

About the role

Set and steer the scientific roadmap for the Lentiviral Vector cell line development (CLD) platform. Perform lentiviral vector stable producer cell line development processes including transfection, pool generation, single cell cloning, clone screening and characterization, and cell banking using state-of-the-art equipment.

More about this role

Our mission at Asimov is to advance humanity's ability to design living systems, enabling biotechnologies with outsized benefit to society. We are developing a mammalian synthetic biology platform––from cells to software––to enable the design and manufacture of next-generation therapeutics.

We are hiring a Senior Scientist to lead our Lentiviral Vector Cell Line Development team in Boston, MA. This role blends strategic leadership with hands-on experimentation, giving you direct influence over our Lentiviral Vector platform roadmap and scientific vision. You will drive the creation of stable producer cell lines for lentiviral vector therapeutics while innovating next-generation cell line development workflows. This is a unique opportunity to work at a nimble, forward-thinking synthetic biology startup and help build the future of biological engineering.

Set and steer the scientific roadmap for the Lentiviral Vector cell line development (CLD) platform.

Perform lentiviral vector stable producer cell line development processes including transfection, pool generation, single cell cloning, clone screening and characterization, and cell banking using state-of-the-art equipment.

Serve...

Read the full posting on Asimov's site ↗

Synthetic Biology

Build your edge while you search

Free tools for founders and investors, plus VC Unfiltered, our take on startups, venture and the people who build them.